Bodenstedt Matthias

SEC source: 0001213900-26-071075 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,115,435

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.87 to $23.2049. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-26-070259 · ownership.xml · nonDerivative · entry 2

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,154,555

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.505 to $19.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-26-070259 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,157,349

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-26-055799 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,172,431

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.83. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-26-044642 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,186,084

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.500 to $19.625. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-26-042629 · ownership.xml · nonDerivative · entry 2

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,188,510

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025 to cover tax liabilities of the Reporting Person.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.500 to $19.560. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-26-042629 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,190,435

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025 to cover tax liabilities of the Reporting Person.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.340 to $19.455. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-26-002907 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,276,305

F1 · kind: Represents shares of restricted stock that vest in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

SEC source: 0001213900-25-124519 · ownership.xml · derivative · entry 3

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A ordinary shares, par value $0.0001 per share · 294,473 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: 15,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On December 19, 2025, the Reporting Person exchanged 8,754 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 294,473 Class A ordinary shares of the Issuer. In connection with the exchange, 294,473 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-124519 · ownership.xml · nonDerivative · entry 2

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · security: 15,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F1 · kind: On December 19, 2025, the Reporting Person exchanged 8,754 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 294,473 Class A ordinary shares of the Issuer. In connection with the exchange, 294,473 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-124519 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 922,009

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On December 19, 2025, the Reporting Person exchanged 8,754 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 294,473 Class A ordinary shares of the Issuer. In connection with the exchange, 294,473 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-097594 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 627,536

F1 · price: The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $9.085 to $9.091244. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001213900-25-019672 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 616,666

F1 · kind: Represents shares of restricted stock that vest in four equal annual installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

SEC source: 0001213900-23-097671 · ownership.xml · nonDerivative · entry 2

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 520,903

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 19, 2023.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $57.53 to $59.27. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-23-097671 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 526,167

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 19, 2023.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $56.655 to $60.13. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001013762-23-001300 · ownership.xml · derivative · entry 3

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,754

Underlying: Class A ordinary shares, par value $0.0001 per share · 62,972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: 15,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 1,872 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 62,972 Class A ordinary shares of the Issuer. In connection with the exchange, 62,972 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001300 · ownership.xml · nonDerivative · entry 2

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 294,473

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · security: 15,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 1,872 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 62,972 Class A ordinary shares of the Issuer. In connection with the exchange, 62,972 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001300 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 620,903

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 1,872 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 62,972 Class A ordinary shares of the Issuer. In connection with the exchange, 62,972 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-23-028294 · ownership.xml · derivative · entry 6

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,626

Underlying: Class A ordinary shares, par value $0.0001 per share · 147,135 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: 15,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest the earlier of (a) 12 months after the occurrence of a Change of Control or (b) the date after the occurrence of the Change of Control on which the holder's employment relationship is terminated.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On April 5, 2023, the Reporting Person exchanged 16,586 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 557,931 Class A ordinary shares of the Issuer. In connection with the exchange, 557,931 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-23-028294 · ownership.xml · derivative · entry 5

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A ordinary shares, par value $0.0001 per share · 410,796 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On April 5, 2023, the Reporting Person exchanged 16,586 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 557,931 Class A ordinary shares of the Issuer. In connection with the exchange, 557,931 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-23-028294 · ownership.xml · nonDerivative · entry 4

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 357,445

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · security: 15,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest the earlier of (a) 12 months after the occurrence of a Change of Control or (b) the date after the occurrence of the Change of Control on which the holder's employment relationship is terminated.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F1 · kind: On April 5, 2023, the Reporting Person exchanged 16,586 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 557,931 Class A ordinary shares of the Issuer. In connection with the exchange, 557,931 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-23-028294 · ownership.xml · nonDerivative · entry 3

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 557,931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On April 5, 2023, the Reporting Person exchanged 16,586 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 557,931 Class A ordinary shares of the Issuer. In connection with the exchange, 557,931 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-23-028294 · ownership.xml · nonDerivative · entry 2

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On April 5, 2023, the Reporting Person exchanged 16,586 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 557,931 Class A ordinary shares of the Issuer. In connection with the exchange, 557,931 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-23-028294 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 410,796

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On April 5, 2023, the Reporting Person exchanged 16,586 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 557,931 Class A ordinary shares of the Issuer. In connection with the exchange, 557,931 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.